Particle.news
Download on the App Store
5 ARTICLES
·
2h ago

Terumo to Acquire Oxford Spinout OrganOx in $1.5 Billion Deal

The deal gives the Japanese medtech group a foothold in transplant technologies built on OrganOx’s FDA-cleared normothermic perfusion platform.

The company’s portable organ preservation device has been used in more than 6,000 liver transplants
Surgeons with OrganOx's metra device (Credit: OrganOx)
handshake-2056023_960_720

Overview

  • Terumo signed a definitive agreement on August 23, 2025 to purchase all outstanding shares of OrganOx, with the final consideration to be determined at completion.
  • OrganOx will become a wholly owned subsidiary of Terumo as the buyer makes a strategic entry into the organ transplantation sector.
  • OrganOx’s metra system is approved in the U.S., EU, UK, Canada and Australia and has supported more than 6,000 liver transplants worldwide.
  • BGF, OrganOx’s largest shareholder, reports proceeds of about £175 million from the sale, marking its biggest return to date.
  • Perella Weinberg Partners and Piper Sandler advised OrganOx with Latham & Watkins as legal counsel, while UK coverage noted concerns about another high-growth medtech moving to overseas ownership.